PE20010699A1 - Nueva formulacion de mirtazapina - Google Patents

Nueva formulacion de mirtazapina

Info

Publication number
PE20010699A1
PE20010699A1 PE2000001100A PE0011002000A PE20010699A1 PE 20010699 A1 PE20010699 A1 PE 20010699A1 PE 2000001100 A PE2000001100 A PE 2000001100A PE 0011002000 A PE0011002000 A PE 0011002000A PE 20010699 A1 PE20010699 A1 PE 20010699A1
Authority
PE
Peru
Prior art keywords
mirtazapine
new formulation
orally
benzazepine
methylpyrazole
Prior art date
Application number
PE2000001100A
Other languages
English (en)
Spanish (es)
Inventor
Nijs Henrik De
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PE20010699A1 publication Critical patent/PE20010699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2000001100A 1999-10-13 2000-10-13 Nueva formulacion de mirtazapina PE20010699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203338 1999-10-13

Publications (1)

Publication Number Publication Date
PE20010699A1 true PE20010699A1 (es) 2001-07-06

Family

ID=8240737

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001100A PE20010699A1 (es) 1999-10-13 2000-10-13 Nueva formulacion de mirtazapina

Country Status (28)

Country Link
EP (1) EP1223914B1 (cg-RX-API-DMAC10.html)
JP (1) JP5561885B2 (cg-RX-API-DMAC10.html)
KR (1) KR100708560B1 (cg-RX-API-DMAC10.html)
CN (1) CN1173701C (cg-RX-API-DMAC10.html)
AR (1) AR026010A1 (cg-RX-API-DMAC10.html)
AT (1) ATE274899T1 (cg-RX-API-DMAC10.html)
AU (1) AU780379B2 (cg-RX-API-DMAC10.html)
BR (1) BR0014593A (cg-RX-API-DMAC10.html)
CA (1) CA2386547C (cg-RX-API-DMAC10.html)
CO (1) CO5251412A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20021315A3 (cg-RX-API-DMAC10.html)
DE (2) DE1223914T1 (cg-RX-API-DMAC10.html)
ES (1) ES2194618T3 (cg-RX-API-DMAC10.html)
HK (1) HK1046641B (cg-RX-API-DMAC10.html)
HU (1) HUP0203148A3 (cg-RX-API-DMAC10.html)
IL (2) IL148777A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA02003519A (cg-RX-API-DMAC10.html)
NO (1) NO20021730L (cg-RX-API-DMAC10.html)
NZ (1) NZ518165A (cg-RX-API-DMAC10.html)
PE (1) PE20010699A1 (cg-RX-API-DMAC10.html)
PL (1) PL200858B1 (cg-RX-API-DMAC10.html)
PT (1) PT1223914E (cg-RX-API-DMAC10.html)
RU (1) RU2261098C2 (cg-RX-API-DMAC10.html)
SK (1) SK6452002A3 (cg-RX-API-DMAC10.html)
TR (1) TR200200978T2 (cg-RX-API-DMAC10.html)
TW (1) TWI256309B (cg-RX-API-DMAC10.html)
WO (1) WO2001026621A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200202293B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474190A1 (en) * 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
EP1689371A2 (en) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Pharmaceutical compositions of mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
WO2007100775A2 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101129341B (zh) * 2006-08-22 2011-06-01 上海医药工业研究院 口内崩解组合物及其制备方法
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
CN102993208B (zh) * 2011-11-22 2017-01-18 北京哈三联科技股份有限公司 去甲肾上腺素和选择性五羟色胺受体阻断剂及其应用
TW201722406A (zh) * 2012-03-02 2017-07-01 羅德製藥公司 抗破壞性立即釋出型調製劑類
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置
JP6601844B2 (ja) * 2016-12-05 2019-11-06 共和薬品工業株式会社 光安定性に優れたミルタザピン含有医薬製剤
CN111714463B (zh) * 2020-08-14 2022-06-17 华农(肇庆)生物产业技术研究院有限公司 米氮平口服剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
EP0737473A1 (en) * 1989-10-02 1996-10-16 Cima Labs, Inc. Effervescent dosage form
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
JPH0436252A (ja) * 1990-05-30 1992-02-06 Nippon Alkyl Alum Kk 光学活性アルキニルアルコールの製造方法
JP3168695B2 (ja) * 1991-06-14 2001-05-21 三菱化学株式会社 ショ糖脂肪酸エステルの置換度の低下方法
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH05163137A (ja) * 1991-12-12 1993-06-29 Shin Etsu Chem Co Ltd 有核顆粒
DE69307908T2 (de) * 1992-10-07 1997-07-10 Akzo Nobel Nv Verfahren zur trennung von enantiomeren aus einer racemischen mischung
JPH0737473A (ja) * 1993-07-27 1995-02-07 Murata Mfg Co Ltd 圧力スイッチ
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JPH10139659A (ja) * 1996-09-10 1998-05-26 Freunt Ind Co Ltd 球形粒子群、その製造方法及びそれを用いた球形粒子製剤
JP3870470B2 (ja) * 1997-02-07 2007-01-17 大正製薬株式会社 マルチプルユニットタイプ徐放性錠剤

Also Published As

Publication number Publication date
DE60013466T2 (de) 2005-01-20
ES2194618T1 (es) 2003-12-01
NZ518165A (en) 2004-03-26
JP2003511403A (ja) 2003-03-25
CO5251412A1 (es) 2003-02-28
AU1023201A (en) 2001-04-23
IL148777A0 (en) 2002-09-12
ES2194618T3 (es) 2005-04-01
EP1223914A2 (en) 2002-07-24
CN1378452A (zh) 2002-11-06
KR100708560B1 (ko) 2007-04-19
HK1046641B (en) 2005-04-08
PT1223914E (pt) 2004-11-30
SK6452002A3 (en) 2002-09-10
TWI256309B (en) 2006-06-11
PL200858B1 (pl) 2009-02-27
PL354584A1 (en) 2004-01-26
IL148777A (en) 2013-10-31
WO2001026621A3 (en) 2001-10-11
DE60013466D1 (de) 2004-10-07
WO2001026621A2 (en) 2001-04-19
HUP0203148A3 (en) 2004-06-28
ZA200202293B (en) 2003-06-20
AR026010A1 (es) 2002-12-26
NO20021730L (no) 2002-05-30
ATE274899T1 (de) 2004-09-15
MXPA02003519A (es) 2002-08-20
KR20020038946A (ko) 2002-05-24
BR0014593A (pt) 2002-06-11
CA2386547A1 (en) 2001-04-19
EP1223914B1 (en) 2004-09-01
NO20021730D0 (no) 2002-04-12
DE1223914T1 (de) 2003-09-18
RU2261098C2 (ru) 2005-09-27
HUP0203148A2 (hu) 2003-01-28
CZ20021315A3 (cs) 2002-07-17
HK1046641A1 (en) 2003-01-24
JP5561885B2 (ja) 2014-07-30
RU2002112238A (ru) 2004-01-10
TR200200978T2 (tr) 2002-09-23
AU780379B2 (en) 2005-03-17
CN1173701C (zh) 2004-11-03
CA2386547C (en) 2010-06-08

Similar Documents

Publication Publication Date Title
IL158041A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL150734A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
NO20015782L (no) Kostblanding eller farmasöytisk sammensetning til anvendelse for forebyggelse eller behandling av hyperoksaluri
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
IL144025A0 (en) A RAS-FARNESYLTRANSFERASE INHIBITOR COMPLEX CONTAINING A 1-4 BENZODIAZEPINE DERIVATIVE AND A β-CYCLODEXTRIN DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
MY135852A (en) Pharmaceutical products
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
HUP9901092A3 (en) Benzimidazole compounds and their pharmaceutical use
IL150223A0 (en) Lipopeptides and pharmaceutical compositions containing the same
AU2002255267A1 (en) An orally administered agent and an orally administered agent/supporting substrate complex
AU2003252478A1 (en) Ccr4 antagonist and medicinal use thereof
IL155937A0 (en) Imidazole and benzimidazole derivatives and pharmaceutical compositions containing the same
AU4687600A (en) Device and method for the administration of oxygen
PL344564A1 (en) Matrix tablet enabling prolonged release of trimethiazidine after oral administration and method of making such tablet
HUP0002324A3 (en) Benzimidazole derivatives and pharmaceutical compositions containing them
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
IL162743A0 (en) Tricyclic 2-pyrimidone derivatives and pharmaceutical compositions containing the same
CA2417887A1 (en) Particulate composition of eletriptan
NO991551D0 (no) Anvendelse av tetrahydrobenz(cd)indol-6-karboksamider i fremstilling av medikamenter for forebyggelse av emesis og behandling av seksuell dysfunksjon
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
IL156372A0 (en) Carbazole derivatives and pharmaceutical compositions containing the same
IL150904A0 (en) Cyclic hexapeptide derivatives and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term